Clinical Significance and Effect of lncRNA HOXA11-AS in NSCLC: A Study Based on Bioinformatics, In Vitro and in Vivo Verification

Zhang, Yu; Chen, Wenjie; Gan, Ting‐Qing; Zhang, Xiuling; Xie, Zucheng; Ye, Zhihua; Deng, Yun; Wang, Ze-feng; Cai, Kai-Teng; Li, Shikang; Luo, Dan; Chen, Gang

doi:10.1038/s41598-017-05856-2

Cited by 43 publications

(50 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, knockdown of HOXA11‐AS inhibited the proliferation, migration, invasion, tumorigenic as well as the angiogenic capability of NSCLC cells and induced apoptosis. HOXA11‐AS also leads to cell cycle arrest at G0/G1 or G2/M phase 10. In another study, Chen et al concluded that HOXA11‐AS was considerably upregulated in NSCLC tissues, compared with that of normal tissues.…”

Section: Hoxa11‐as Lncrna In Human Cancersmentioning

confidence: 99%

HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers

Zhou

Xie

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

The cancers are the leading cause of disease‐related deaths worldwide with a high risk of morbidity and mortality. Long noncoding RNAs (lncRNAs) play a critical role in a wide range of biological processes, including tumorigenesis. HOXA11‐AS (NCRNA00076), the antisense strands of HOXA11 gene, was initially revealed in a mouse embryonic cDNA library in 2009 and it was a fairly novel lncRNA. This review summarized the advanced research progression concerning the expression and role of HOXA11‐AS in different human malignancies. The expression of HOXA11‐AS is aberrantly altered in many cancers, either as a tumor suppressor or as a tumor accelerator. The different underlying mechanism of HOXA11‐AS in different cancers (including, nonsmall cell lung cancers, osteosarcoma, uveal melanoma, glioma, hepatocellular carcinoma, gastric cancer, breast cancer, cervical cancer, ovarian cancer, colorectal cancer, ovarian cancer, and glioblastoma) was also detailed. These findings lead us to conclude that HOXA11‐AS participate in the complex network of cancers and plays an important role in the tumorigenesis and progression. Functional HOXA11‐AS could be a promising biomarker for early detection as well as prognosis evaluation in cancer patients. Future HOXA11‐AS‐targeted intervention may become a valuable novel therapeutic tool, improving the clinical management of cancers.

show abstract

Section: Hoxa11‐as Lncrna In Human Cancersmentioning

confidence: 99%

HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers

Zhou

Xie

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…13 Studies have found that lncRNA are abnormally expressed in NSCLC, and they regulate the development of NSCLC by stimulating or inhibiting biological processes. 14,15 LncRNA LINC01194 was discovered as a new lncRNA. Studies have confirmed that LINC01194 levels in breast cancer tissues are significantly lower.…”

Section: Introductionmentioning

confidence: 99%

<p>The lncRNA LINC01194/miR-486-5p Axis Facilitates Malignancy in Non-Small Cell Lung Cancer via Regulating CDK4</p>

Xing¹,

Zhang²,

Gao³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: This experimental design was based on lncRNA LINC01194 to explore the pathogenesis of NSCLC. Methods: RT-qPCR was used to detect the expression of lncRNA LINC01194 and miR-486-5p in NSCLC tissues and cell lines. CCK-8, colony formation, and transwell assays were used to examine the effects of lncRNA LINC01194 and miR-486-5p on NSCLC cell proliferation and migration invasiveness. For target gene prediction and screening, luciferase reporter assays were used to verify downstream target genes for lncRNA LINC01194 and miR-486-5p. The protein expression of CDK4 was detected using Western blotting. The tumor changes in mice were detected by in vivo experiments in nude mice. Results: LncRNA LINC01194 was highly expressed in NSCLC tissues and NSCLC lines (A549, H1299, H460 cells, H1975), and lncRNA LINC01194 significantly promoted cell proliferation and migration of NSCLC cells. MiR-486-5p was identified as a potential target for LINC01194, and miR-486-5p was expressed at a low level in NSCLC tissues and NSCLC lines (A549, H1299, H460 cells, H1975). CDK4 was identified as a potential target for miR-486-5p. LncRNA LINC01194 was able to inhibit miR-486-5p expression and upregulate the expression level of CDK4. Finally, the results of in vivo animal models confirmed that lncRNA LINC01194 promoted NSCLC progression by modulating the miR-486-5p/CDK4 axis. Conclusion: LncRNA LINC01194 promoted the progression of NSCLC by modulating the miR-486-5p/CDK4 axis.

show abstract

“…Specifically, numerous studies have demonstrated that lncRNAs are critically involved in lung cancer progression. Recently, Zhang et al showed that lncRNA HOXA11-AS promotes tumorigenesis in NSCLC through a chick embryo chorioallantoic membrane (CAM) model [10]. Cui et al showed that SNHG1 promotes NSCLC progression via targeting miR-101-3p and modulates Wnt signaling [11] Instead, TFPI2AS1 may function as a tumor suppressor in NSCLC progression by increasing the expression of cyclin D1 and cyclin-dependent kinases 2 (CDK2) [12].…”

Section: Introductionmentioning

confidence: 99%

The long non-coding RNA LSINCT5 promotes malignancy in non-small cell lung cancer by stabilizing HMGA2

et al. 2018

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) can actively participate in tumorigenesis in various cancers. However, the involvement of lncRNA long stress induced non-coding transcripts 5 (LSINCT5) in non-small cell lung cancer (NSCLC) remains largely unknown. Here we showed a novel lncRNA signature in NSCLC through lncRNA profiling. Increased LSINCT5 expression positively correlates with malignant clinicopathological features and poor survival. LSINCT5 can promote migration and viability of various NSCLC cells in vitro and also enhance lung cancer progression in vivo. RNA immunoprecipitation followed by mass spectrometry has identified that LSINCT5 interacts with HMGA2. This physical interaction can increase the stability of HMGA2 by inhibiting proteasome-mediated degradation. Therefore, LSINCT5 may possibly contribute to NSCLC tumorigenesis by stabilizing the oncogenic factor of HMGA2. This novel LSINCT5/HMGA2 axis can modulate lung cancer progression and might be a promising target for pharmacological intervention.

show abstract

Clinical Significance and Effect of lncRNA HOXA11-AS in NSCLC: A Study Based on Bioinformatics, In Vitro and in Vivo Verification

Cited by 43 publications

References 56 publications

HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers

HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers

<p>The lncRNA LINC01194/miR-486-5p Axis Facilitates Malignancy in Non-Small Cell Lung Cancer via Regulating CDK4</p>

The long non-coding RNA LSINCT5 promotes malignancy in non-small cell lung cancer by stabilizing HMGA2

Contact Info

Product

Resources

About